Larimar Therapeutics, Inc. develops treatments for complex rare diseases, with its lead program, nomlabofusp, focused on Friedreich’s ataxia. Nomlabofusp is a subcutaneously administered recombinant fusion protein designed to deliver frataxin to mitochondria, and company updates frequently address clinical data, frataxin measurement, FDA interactions and regulatory designations tied to that program.
Recurring LRMR news also covers operating and financial results, equity financing activity, corporate presentations and research publications related to its intracellular delivery platform. The company’s disclosures connect program development with capital needs, rare-disease regulatory pathways and the broader use of fusion proteins for diseases involving intracellular bioactive-compound deficiencies.
Larimar Therapeutics (Nasdaq: LRMR) appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to CEO Carole Ben-Maimon.
Harlow brings more than 25 years of commercial, operational and business development experience and most recently served as Esperion Therapeutics’ Chief Commercial Officer. Larimar said his appointment supports organizational scaling and preparations for nomlabofusp’s potential approval.
His inducement awards comprise options to purchase 800,000 shares at the grant-date closing price and restricted stock units covering 50,000 shares. Options vest over four years: 25% on the first anniversary and the remaining 75% in substantially equal monthly installments over 36 months. Restricted stock units vest in four substantially equal annual installments beginning on the first anniversary. Both awards require continued service through applicable vesting dates.
Century Therapeutics (IPSC) has appointed biotechnology executive Joseph Truitt to its Board of Directors.
Truitt is Chief Executive Officer and a director of iECURE, serves as Chairman of the Board of Larimar Therapeutics (LRMR), and sits on the Board of Code Biotherapeutics. He previously held senior leadership roles at BioSpecifics Technologies and Achillion Pharmaceuticals, both acquired by larger pharmaceutical companies.
The appointment comes as Century advances CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, toward an IND submission targeted for the fourth quarter of 2026 after an FDA pre-IND meeting that aligned on key development elements, and prepares CNTY-308, a CD19-targeted CAR-iT cell therapy for B-cell-mediated diseases, for anticipated clinic entry in 2026. Both candidates use the company’s Allo-Evasion™ 5.0 platform.
Larimar Therapeutics (Nasdaq: LRMR) reported second quarter 2026 results and progress for its lead Friedreich’s ataxia (FA) candidate, nomlabofusp. A long-term open-label study in 43 adolescents and adults has generated more than 10,000 doses, showing sustained frataxin (FXN) increases, a generally consistent safety profile, and a 2.6‑point mFARS benefit at one year versus the FACOMS natural history population. Anaphylaxis occurred in 10 participants and generalized urticaria in three, all resolving with standard therapy and leading to discontinuation.
Following a multidisciplinary Type B pre-BLA meeting, the FDA agreed a rolling BLA seeking accelerated approval is acceptable, with FXN considered a potential surrogate endpoint. The first BLA module has been submitted; completion is expected in 2H 2026 and first dosing in a global confirmatory Phase 3 is anticipated in Q3 2026. Larimar ended June 30, 2026 with $156.3 million in cash, cash equivalents and marketable securities, projecting runway into Q3 2027, and reported a Q2 2026 net loss of $32.8 million.
Larimar Therapeutics (Nasdaq: LRMR) submitted the first module of a rolling BLA to the FDA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, with remaining modules expected in 2H 2026.
Open-label data show sustained skin FXN increases, directional clinical improvements versus a FACOMS reference group, and a generally consistent safety profile including anaphylaxis events.
Larimar Therapeutics (Nasdaq: LRMR) will host an investor webcast on Monday, June 29, 2026, at 7:45 a.m. ET.
The event will cover updates on the nomlabofusp clinical development program for Friedreich’s ataxia, including a regulatory update and data from an ongoing long-term open-label study. An archived webcast will be available afterward on Larimar’s website.
Larimar Therapeutics (Nasdaq: LRMR) reported Q1 2026 results and clinical progress for nomlabofusp in Friedreich’s ataxia. The company plans to seek accelerated approval via a rolling BLA, starting June 2026 with nonclinical and clinical modules and submitting final CMC-related modules in the second half of 2026.
Nomlabofusp has Breakthrough Therapy Designation, supportive cross-species FXN data, and a global Phase 3 set to begin dosing mid-2026. Larimar held $200.4 million in cash and securities on March 31, 2026, projecting runway into Q2 2027, and reported a Q1 2026 net loss of $29.6 million.
Larimar Therapeutics (Nasdaq: LRMR) published a peer-reviewed article reporting that treatment with nomlabofusp raised frataxin (FXN) levels across mice, rats, non-human primates and in patients with Friedreich’s ataxia (FA).
Measured FXN increases in accessible peripheral tissues (skin, buccal cells) correlated with levels in clinically relevant organs; these data were reviewed by the FDA in support of the potential use of skin FXN as a reasonably likely surrogate endpoint. Larimar plans a BLA submission in June 2026 and to pursue accelerated approval.
Larimar Therapeutics (NASDAQ: LRMR) reported Q4 and full‑year 2025 results and provided clinical and financing updates. Key items: Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, topline open‑label data expected Q2 2026, planned BLA submission in June 2026, Phase 3 screening to start Q2 2026, and U.S. launch targeted H1 2027 if approved.
Balance sheet: pro forma cash of $244.5M and projected runway into Q2 2027 after a $107.6M net public offering. Reported full‑year net loss $165.7M; increased R&D investment to support commercialization.
Larimar Therapeutics (Nasdaq: LRMR) announced management will present and hold 1x1 investor meetings at two Miami Beach investor conferences in March 2026.
Presentations: Leerink Partners Global Healthcare Conference on March 10, 2026 at 8:40 AM ET and Citizens Life Sciences Conference on March 11, 2026 at 4:00 PM ET. Replays will be available for 30 days on Larimar’s Events and Presentations page.
Larimar Therapeutics (Nasdaq: LRMR) priced an upsized underwritten public offering of 20,000,000 common shares at $5.00 per share, yielding expected gross proceeds of $100 million before expenses. The underwriters have a 30‑day option for an additional 3,000,000 shares.
The offering is expected to close on or about February 27, 2026. Larimar said net proceeds will support development of nomlabofusp and fund working capital, R&D and commercialization expenses. The offering uses an effective Form S-3 shelf registration (effective May 24, 2024).